X4 Pharmaceuticals Q3 Net Loss Narrows 32% to $20.2 Million

Bitget2026/11/04 22:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

X4 Pharmaceuticals’ third-quarter 2026 net loss narrowed 32% year over year to $20.2 million.
Revenue climbed 63% year over year to $2.88 million.
Cash, cash equivalents and marketable securities totaled $187.7 million at September 30, with cash runway extending into Q1 2029.
The 4WARD trial targets enrollment completion in Q4 2026, with topline results from 4WARD and 4STEPS expected in Q1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041615PRIMZONEFULLFEED9870506) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

X4 Pharmaceuticals Q3 Net Loss Narrows 32% to $20.2 Million

You may also like

Crypto prices